Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2014

View Archived Issues

Oasmia's paclitaxel formulation shows non-inferiority to Taxol in phase III trial

Rheumatoid arthritis candidate BI-638683 well tolerated in phase I study

CKD-L, an HDAC6 inhibitor, may have potential for the treatment of RA

Phase I results for the rituximab biosimilar PF-05280586

New CFTR correctors prepared at DiscoveryBiomed

Biogen Idec discloses novel autotaxin and S1P1 receptor modulators

Irish and Belgian university researchers report novel HIV-1 RT inhibitors

Roche prepares agents for neurodegenerative disorders

Portuguese group designs new agents for tuberculosis

DARA BioSciences' KRN-5500 receives U.S. orphan drug designation for multiple myeloma

Takeda to withdraw Omontys NDA and terminate license with Affymax

Novartis submits BLA to the FDA for meningitis B vaccine candidate

Merck KGaA and Ono Pharmaceutical terminate license agreement for ceralifimod

German researchers divulge new agents for cancer

Collaborative biomarker-driven Lung-MAP trial to test five approaches for NSCLC

Radiosynthesis and microPET evaluation of F-18 CRF1 receptor PET tracer presented

Biogen Idec and AbbVie report topline data from phase III daclizumab high-yield process trial

Can-Fite BioPharma completes enrollment in phase II/III CF-101 trial

EIB to provide codevelopment funding to UCB

Mocetinostat receives FDA orphan drug designation in myelodysplastic syndrome

Caplacizumab achieves clinical proof-of-concept in phase II TITAN study

FDPA shows potential for imaging bacterial infections in the lung

Takeda launches Zacras and new Azilva dosage in Japan

FDA grants fast track status to DNX-2401 for recurrent glioblastoma

Symplmed files for approval of hypertension combination in the U.S.

Pfizer files BLA for Neisseria meningitidis serogroup B vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...